The impact and relationship of inflammatory markers and radiologic involvement in the COVID-19 patients

Abstract

Aim: In the study, it was aimed to investigate the relationship between inflammatory markers and radiology in COVID-19 patients. Material and Method: The study was conducted in the quarantine wards of a tertiary hospital between March and June 2020. Patients with a definite diagnosis of COVID-19 were included in the study. The lung damage of the patients caused by COVID-19 was determined by computed tomography and the relationship between lung damage and inflammatory markers was examined. Results: The mean age of 259 COVID-19 patients included in the study was 61.96 ± 14.076. Except for thrombocytopenia, all variables such as ferritin, D-dimer, thoracic computerized tomography (CT) involvement rates were significantly poorer in the patients requiring the care in ICU than the patients in wards (p<0.001). No chronic disease was found in 193 (74.5%) of 259 patients. In multi-variate analyzes, elderly and high thoracic CT involvement rate were determined as independent variables determining the serious disease risks and are important parameters in assessing the need for ICU (p<0.05). Ferritin value, D-Dimer value on the third day of admission, Neutrophil lymphocyte ratio and leukocyte count were found to be correlated with thoracic CT involvement rate (p <0.05). Conclusion: It was observed that there were serious changes in the infection parameters of COVID-19 cases with advanced radiological involvement in the lung.

Keywords

• COVID-19
• intensive care unit
• prognosis
• SARS-CoV-2

Project Number

Yok

References

1. Khabbaz R, Beth BP, Schuchat A, et al. Emerging and reemerging infectious disease threats. In: Mandel, Dougles, and Bennett’s Principles and Practice of Infectious Disease, Bennett JE, Dolin R, Blaser MJ (eds). 8rd ed. Philadelphia: Elsevier; 2015: 158-77.
2. World Health Organization: COVID-19 Weekly Epidemiological Update-24 November 2020. Available at: Accessed November 25, 2020.
3. Cao W, Li T. COVID-19: towards understanding of pathogenesis. Cell Res 2020; 5: 367–9.
4. Shi Y, Yu X, Zhao H, et al. Host susceptibility to severe COVID-19 and establishment of a host risk score: Findings of 487 cases outside Wuhan. Crit Care 2020; 1: 2–5.
5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. Jama 2020; 13: 1239-42.
6. Zhai P, Ding Y, Wu X, et al. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020; 5: 105955.
7. TR Ministry of Health, General Directorate of Public Health. COVID-19 (SARS-CoV-2 Infection) Treatment of Adult Patients 19 June 2020. Available at: . Accessed July 1, 2020.
8. Pan F, Ye T, Sun P. Time course of lung changes at chest ct during recovery from coronavirus disease 2019 (COVID-19). Radiology 2020; 295: 715–21.

9. Li K, Wu J, Wu F, et al. The clinical and chest ct features associated with severe and critical COVID-19 pneumonia. Invest Radiol 2020; 6: 327-31.
10. China-WHO Expert team . Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available at . Accessed by July 1,2020.
11. World Health Organization: Clinical Care Severe Acute Respiratory Infection: Tool kit. Available at: < https://apps.who.int/iris/bitstream/handle/10665/331736/WHO-2019-nCoV-SARI_toolkit-2020.1-eng.pdf?sequence=1&isAllowed=y>. Accessed by July 1, 2020.
12. Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19) : A literature review. J Infect Public Health 2020; 5: 667–73.
13. Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020; 76: 71–6.
14. Shi Y, Wang G, Cai XP, et al. An overview of COVID-19. J Zhejiang Univ Sci B 2020; 5: 343–60.
15. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91–5.
16. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 2020; 50: 620–32.
17. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020; 4: 425-34.
18. Li R, Tian J, Yang F, et al. Clinical characteristics of 225 patients with COVID-19 in a tertiary hospital near Wuhan, China. J Clin Virol 2020; 127: 104363.
19. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 18: 1708–20.
20. Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020; 6: 1324–9.
21. Kamps BS, Hoffmann C (editors). Diagnostic Tests and Prosedures. In: COVID reference. Fourth ed., Hamburg: Steinhauser-Verlag; 2020: 155-85.
22. World Health Organization: Use of chest imaging in COVID-19. Available at: https://www.who.int/publications/i/item/use-of-chest-imaging-in-covid-19. Accessed by July 1, 2020.
23. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019 (COVID-19): A systematic review of ımaging findings in 919 patients. AJR Am J Roentgenol 2020; 1: 87–93.
24. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 3: 105924.
25. Song F, Shi N, Shan F, et al. Emerging 2019 novel coronavirus (2019-NCoV) pneumonia. Radiology 2020; 1: 210–7.